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Abstract
Visceral leishmaniasis (VL) is a neglected tropical disease (NTD) caused
by  protozoa that are transmitted by female sand flies. On theLeishmania 
Indian subcontinent (ISC), VL is targeted by the World Health Organization
(WHO) for elimination as a public health problem by 2020, which is defined
as <1 VL case (new and relapse) per 10,000 population at district level in
Nepal and sub-district level in Bangladesh and India. WHO is currently in
the process of formulating 2030 targets, asking whether to maintain the
2020 target or to modify it, while adding a target of zero mortality among
detected cases. The NTD Modelling Consortium has developed various
mathematical VL transmission models to gain insight into the transmission
dynamics of VL, identify the main knowledge gaps, and predict the
feasibility of achieving and sustaining the targets by simulating the impact of
varying intervention strategies. According to the models, the current target
is feasible at the appropriate district/sub-district level in settings with
medium VL endemicities (up to 5 reported VL cases per 10,000 population
per year) prior to the start of the interventions. However, in settings with
higher pre-control endemicities, additional efforts may be required. We also
highlight the risk that those with post-kala-azar dermal leishmaniasis
(PKDL) may pose to reaching and sustaining the VL targets, and therefore
advocate adding control of PKDL cases to the new 2030 targets. Spatial
analyses revealed that local hotspots with high VL incidence remain. We
warn that the current target provides a perverse incentive to not
detect/report cases as the target is approached, posing a risk for truly
achieving elimination as a public health problem although this is taken into
consideration by the WHO procedures for validation. Ongoing modelling
work focuses on the risk of recrudescence when interventions are relaxed
after the elimination target has been achieved.
Keywords
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Disclaimer
The opinions expressed herein are those of the authors and do not 
necessarily reflect the views of the World Health Organization. 
Publication in Gates Open Research does not imply endorsement 
by the Gates Foundation.
Background
Visceral leishmaniasis (VL) is a neglected tropical disease (NTD) 
caused by Leishmania protozoa that are transmitted by infected 
female sand flies. Most individuals remain asymptomatic, but 
those that develop symptoms experience long-lasting fever 
and hepatosplenomegaly, and die when left untreated1. About 
5–10% of treated individuals develop a skin condition called 
post-kala-azar dermal leishmaniasis (PKDL)2. Interventions 
include active case detection (ACD) of VL followed by 
prompt treatment, and vector control through indoor residual 
spraying of insecticide (IRS).
The World Health Organization (WHO) has targeted the 
elimination of VL as a public health problem on the Indian 
subcontinent by 2020, defined as <1 VL case (new case and 
relapse) per 10,000 population per year, at the district level in 
Nepal and sub-district level in Bangladesh and India3. To achieve 
this target, the associated WHO guidelines describe four phases: a 
pre-control preparatory phase; a 5-year attack phase designed 
to bring the incidence below 1 per 10,000 per year; a consolida-
tion phase where incidence is kept below the target for 3 years; 
and a maintenance phase to ensure sustainable reductions in 
incidence4. The interventions associated with these phases 
entail different levels of ACD and IRS. With 2020 approaching, 
WHO is in the process of formulating targets for 2030 for 
the Indian subcontinent, asking stakeholders in the VL 
community whether to maintain the 2020 target or to modify it, 
while adding the target of zero mortality among detected cases. 
The stakeholders include endemic country representatives, 
implementing partners, donors, mathematical modellers, WHO 
staff, and others, and were all invited to provide ideas and 
feedback on the new 2030 WHO targets (April–July 2019).
Mathematical transmission models have proven useful tools 
in gaining insight into the transmission dynamics of infectious 
diseases, highlighting knowledge gaps, and predicting the 
impact of interventions, to ultimately inform policy mak-
ers in formulating optimal strategies5. The Bill-and-Melinda- 
Gates-Foundation-funded NTD Modelling Consortium was 
founded in 2014, bringing together multiple groups working on 
the modelling of NTDs, including VL, with VL modelling teams 
from The Netherlands (Erasmus MC) and the United Kingdom 
(Warwick University, London School of Tropical Medicine and 
Hygiene, and Oxford University)6. In close collaboration with 
disease experts and policy makers, the VL teams captured the 
transmission dynamics of VL with mathematical models7,8, 
compared their models through geographical cross-validation9, 
and published a joint policy paper10. Even though the models 
had certain different underlying assumptions regarding the main 
knowledge gaps, such as the role of asymptomatic individuals, 
PKDL cases, the duration of immunity, and the actual quality 
of the interventions, the models generally agreed on the 
predicted trends towards elimination. In this Open Letter we 
present an overview of the main VL modelling outcomes to 
support the development of the new WHO 2030 VL targets.
Insights gained from mathematical modelling analyses
Model predictions have suggested that the current intervention 
guidelines recommended by the WHO are sufficient to reach the 
elimination target in areas with moderate VL incidence (up to 
5 reported VL cases per 10,000 population per year) prior to 
the start of interventions. However, additional interventions, 
such as extending the WHO attack phase (intensive IRS and 
ACD), may be required to achieve the elimination target in 
regions with high pre-control incidence, depending on the relative 
infectiousness of different disease stages. As VL incidence 
decreases, the pool of susceptible individuals will grow, creating 
the potential for new outbreaks10.
Despite the overall decrease in VL incidence at sub-district 
level, clusters or ‘hotspots’ of high incidence within sub-districts 
remain. We studied these hotspots at hamlet (sub-village) level 
using geospatial analyses and found significant spatial and 
temporal heterogeneity in VL incidence. Based on these find-
ings, we argue for considering lower geographical units for 
evaluation of control after the targets at district/sub-district level 
have been achieved11. Another key issue is the spatial spread of 
infection at an even smaller scale, between human hosts. Our 
modelling work suggests that case-to-case transmission is local 
(≤500 m)11–13, which would support the current range of IRS 
around affected villages. However, the value of IRS, as it is 
currently implemented, has been questioned14,15, whereas there 
is some indirect evidence for the impact of diagnosis and 
treatment14,16,17, making case detection pivotal in the elimina-
tion programme. Moreover, even though this is currently not the 
target, no geographical areas have been “cleared” of transmis-
sion, suggesting that current tools are not sufficient to achieve 
zero transmission and may have to be implemented indefi-
nitely to maintain control. Incomplete understanding of the 
spatiotemporal variation in VL incidence and its importance 
for achieving elimination as a public health problem and/or 
interrupting transmission undermines our ability to provide 
advice on the most appropriate geographical level to evaluate 
programme impact.
Recent xenodiagnostic studies have found PKDL can be at 
least as infectious as VL, depending on skin lesion type and 
severity18. When incorporating this into our models, PKDL 
becomes an important source of transmission, especially when 
nearing the low-incidence VL elimination target10,19, likely 
challenging the maintenance of the elimination target on the 
Indian subcontinent. When adding a hypothetical PKDL control 
strategy (e.g. preventing 95% of PKDL) to the existing WHO 
strategy, the elimination target can be achieved as much as 
8 years earlier, when keeping the assumption that only 2.5% of 
past VL cases develop PKDL constant19. Currently, the main 
intervention programmes do not include PKDL control. The 
main reason is that the options for diagnosing and treating this 
skin condition are limited. Ideally, active PKDL case-finding and 
treatment would be implemented, through long-term follow-up 
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of VL patients, patient education to report themselves to the 
health clinic when symptoms of skin discoloration or rash 
appear, and educating community workers on recognizing 
PKDL. However, the suggested strategies are operationally 
difficult and require the availability of safe and effective 
treatment. There is a clear need for better VL treatment 
options, including a vaccine or immunomodulator to avert any 
PKDL development, and diagnostics for PKDL.
It is unclear to what extent interventions have contributed to 
the decline in VL incidence in addition to the secular trend in 
VL incidence, as some decline may be due to long-term 
(~15-year) natural cycles20–22. However, transmission models 
suggest that interventions are likely to have contributed 
significantly to the decline over the last 5 years. Large village-
level outbreaks of disease are still to be expected and have been 
observed in the field (e.g. Kosra23)24,25, with recent stochastic 
modelling work reproducing those trends12. From the point of 
view of achieving the target of 1 per 10,000 cases in each block 
(sub-district level in India), due to the high variability in case 
numbers at this level, it is statistically implausible that the 
target can be achieved in all blocks simultaneously. This 
variation means that whilst low endemicity is maintained, the 
current target will fail at some point, as has occurred recently in 
Nepal26. This suggests that the choice of administration level at 
which to assess elimination as a public health problem is critical 
to attaining and maintaining the target.
Table 1 summarizes the modelling insights and challenges for 
reaching the WHO 2030 targets. In Table 2 we summarize the 
priority questions that were identified in discussions with WHO and 
present how modelling can address this.
Practical implications of the currently proposed 
targets
Timeline and feasibility
The VL elimination target of <1 VL case per 10,000 
population per year is feasible in most sub-districts (and larger 
administrative units)7,9,10, but at lower geographical levels 
small outbreaks will continue to occur with case incidence 
above the target due to ongoing transmission from undiagnosed 
VL cases, PKDL cases, potentially asymptomatic cases, and 
those with HIV-VL co-infection. The goal of zero deaths among 
detected cases is feasible with current treatments if there is 
stringent post-treatment follow up. However, undiagnosed cases 
may still die of VL as they remain untreated.
Moreover, operationally it is challenging to successfully 
implement active case detection in all villages; the best 
intervention would prevent outbreaks, and not “follow” them. 
Currently, it is not possible to predict when and where 
outbreaks will occur in order to target control efforts. Future 
modelling work may be able to help identify useful markers to 
predict high-risk areas.
Ability to sustain achievement of the goal
Continued case detection at the current level is required 
otherwise there is a risk that incidence will resurge10,19. Active 
follow-up of treated cases is required to ensure treatment 
success and detect relapse cases and cases of PKDL (90% of 
PKDL cases occur among treated VL cases)2. Treatment 
availability and effectiveness will need to be sustained. New 
drugs will eventually need to be developed, ideally those that 
do not require a cold chain. Health system and community 
awareness will need to be maintained to ensure cases are 
Table 1. Summary of modelling insights and challenges for reaching the WHO 2030 targets for visceral leishmaniasis.
Current WHO 2020 target on the 
Indian subcontinent:
Elimination of VL as a public health problem, defined as <1 VL case (new and relapse) per  
10,000 population per year, at district/sub-district level.
Proposed WHO 2030 target on the 
Indian subcontinent:
Elimination of VL as a public health problem, defined as <1 VL case (new and relapse) per  
10,000 population per year, at district/sub-district level and zero deaths among detected cases. The 
administrative level could be adjusted if discussion between VL stakeholders, WHO, and ministries 
of health (MOH) of affected countries lead to acceptance by the MOH to modify it. Reducing the 
administrative level, would lower the population size and therefore better reflect the population at risk 
of VL, but would enhance the variability in incidence.
Is the new target technically 
feasible under the current disease 
strategy?
VL incidence and relapse of <1/10,000/year seems feasible in most regions at district level and 
higher, but not at smaller geographical scales.
If not, what is required to achieve 
the target? (updated strategy, use 
of new tools, etc.)
Additional data streams (to ensure case detection is complete); means to assess and prevent occult 
transmission; means to predict outbreaks; means to detect and treat PKDL more completely and 
earlier; more specific diagnostics for earlier treatment of cases, and the reporting of relapses.
Are current tools able to reliably 
measure the target?
No, the targets are defined in terms of numbers of reported diagnoses and deaths, which likely 
provides an incomplete picture of actual case incidence and mortality, and poses a perverse 
incentive for complete reporting.
What are the biggest unknowns? The duration of immunity, the impact of indoor residual spraying of insecticide (IRS), the role of 
asymptomatic individuals, true VL incidence (besides reported incidence), and how changes in 
detection delay and population coverage affect VL transmission.
What are the biggest risks? Presence of PKDL and lack of tools to effectively diagnose, treat, and prevent. 
The current target provides a perverse incentive to not detect/report cases as the target is 
approached. 
Risk of recrudescence when interventions are relaxed after achieving the low-incidence target. 
Continued outbreaks at village level combined with increasing susceptibility leading to widespread 
and sustained epidemics.
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detected. A more specific diagnostic that could detect pre-clinical 
cases without delay could have major impact17.
Measuring the target
The numbers of cases diagnosed at the block level is very 
heterogeneous (many zeros and some occasional high numbers, 
e.g. 36 in one block in one month in India). With >600 endemic 
blocks in India it is statistically infeasible that all blocks will be 
below target for 3 consecutive years. This “failure” is in spite 
of the undoubted reduction in number of cases. Moreover, the 
current target creates a perverse incentive to not detect/register 
cases when approaching, and after having reached, the tar-
get (see paragraph below “Where are the places of perverse 
incentive?”). Models suggest complete case detection and 
treatment may be more important than reducing the delay to 
treatment to <45 days among diagnosed cases (while still 
missing cases) to reduce transmission17. Nevertheless, the 
current target ensures programme effectiveness and appropriate 
health system engagement. Xenomonitoring, antigen detec-
tion, and serosurveillance are potential independent measures of 
transmission that are being developed under the SPEAK India 
consortium. Measuring mortality can be challenging, as it 
requires governments to follow the TDR/WHO manual for death 
definition and share these data with WHO as part of the validation 
procedure.
Considerations of cost
Lenk et al. estimated how much of the income loss faced by 
individuals affected with VL would be avoided by reaching 
the global WHO targets, based on the number of averted cases 
and deaths when achieving and sustain#ing the targets27. The 
total economic benefit from globally averted productivity loss 
in the period 2011-2030 when reaching the WHO targets for VL 
was calculated to be 21.3 billion I$1, of which 15.1 I$ (70%) are 
from reaching the targets in India. The out-of-pocket payments 
(OPPs) for an individual with VL in India were found to be 
I$ 354.7528. According to the literature, 80% of all patients were 
being treated in India29–31, and this percentage was assumed to 
remain constant until 2030 in this study. The percentage of 
patients paying for treatment was assumed to linearly decrease 
to zero in 2030, considering universal health coverage. The total 
economic benefit from globally averted OPPs for VL added up to 
270 million I$ for the period 2011-2030.
WHO has estimated that the economic benefits of achieving the 
VL target are higher than the cost of the required investments, 
resulting in a net return on investment32. It was calculated 
that for VL, the net benefit2 was 3.5 USD for every dollar 
invested in the period 1990-2030 (adapted from 32). Hence, 
it was considered that the financial efforts that are required to 
reach the WHO VL targets are justified.
Where are the risks that need to be mitigated to achieve 
the stated goals?
The current focus of the control programme is in the so-called 
“endemic” administrative units, although the actual defini-
tion used for this classification is unclear. This also means that 
the “non-endemic” units can have unobserved and uncontrolled 
transmission. The experience of the control programme has been 
that the “endemic” region appears to have expanded even as the 
incidence of cases has fallen25 possibly due to human mobility 
combined with late development of PKDL and potential 
transmission from asymptomatic individuals, and/or an increase 
in case detection. Moreover, human mobility and migration 
might provide a constant “trickle” of transmission. Infrequent 
large epidemics (e.g. Kosra23), and continued low-level 
transmission in Nepal26,34 suggest that both of these occur.
Overall, poor understanding of the spatiotemporal variation in 
VL incidence and its importance for achieving control and/or 
interrupting transmission undermines our ability to provide 
advice on the most appropriate geographical level to evaluate 
programme impact. Fine-scale geographical measurement will 
lead to high variation over time and space whereas a lower spa-
tial resolution (i.e. aggregating M&E results over larger areas) 
will come with a risk of missing programme failure at a more 
local level. Additional risks include the perverse incentive 
to not detect/register cases in order to ensure the target is 
achieved; natural disasters that could disrupt detection of cases 
(e.g. flooding in Raghopur block, India in August 2017 
disrupted control); and the potential rise of HIV and its interaction 
with VL that could drive local resurgent epidemics35.
Where are the places of perverse incentive?
Diagnosis and treatment are critical for ongoing VL control 
(i.e. to attain and maintain elimination as a public health 
problem). Targets should encourage diagnosis and treatment, but 
the “knife-edge” target encourages cases not to be diagnosed/
treated/reported if it will mean that the block (and therefore 
country) fails to reach or sustain the target. The WHO vali-
dation process includes analyses to ensure that the claimed 
elimination is not due to underreporting4. The average block 
size in India is ~200,000, at which the target is 20 cases: 21 is 
failure and 19 is success. At the recent meeting WHO suggested 
to create other categories instead of success/fail such as very 
low/low/medium/high/very high. Such a target could encourage 
case finding and detach the success/failure of the target from 
finding of a single case in a block. Another suggestion is to 
report a detected case as a person who has been diagnosed, 
treated, and has not died. In this way it could be a positive 
incentive by saying “number of lives saved”. Other suggestions 
include setting an incidence target of 1/20,000 at the district 
level, or setting a target to increase the proportion of cases 
coming from low-incidence blocks, such as done in the 
Americas.
1An international dollar (I$) would buy in the cited country or countries a 
comparable amount of goods and services a U.S. dollar would buy in the 
United States33.
2Only investments in individual management of VL were included, as well 
as active case finding and vector control (only in areas of the Indian subcon-
tinent that are not co-endemic with malaria).
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Table 2. Summary of priority questions identified in discussion with WHO and how modelling can address this.
Priority questions identified in 
discussion with WHO
How can modelling address this?
What would be an ambitious but 
achievable goal for 2030?
To switch the target to <1/20,000/year at the district level or making sure that the vast 
majority of cases is coming from blocks with incidence <1/20,000/year in the previous year. 
How good can the health system be? What 
would be a realistic number of deaths 
seen in treated individuals? (in the context 
of zero deaths goal)
Our current models do not specifically tackle how the health system can change to reduce 
mortality in treated cases; what we can say is how much mortality in the population as a 
whole can be reduced if more undetected cases are found and treated.
Once the targets are met, would it lead 
naturally to the elimination of transmission 
of VL?
We have attempted to answer this question in existing modelling publications, notably6. An 
important factor is the presence of a large susceptible population once the targets are met, 
potentially with PKDL cases still present that remain infectious for years, that could cause 
recrudescence of infection. 
The existing models now need to be reviewed and revised to reflect improved understanding 
of local transmission in small populations that are interlinked.
What do the models suggest is the likely 
probability of achieving the goals?
According to the deterministic transmission models, the 2020 target is feasible at the 
appropriate district/sub-district level in settings with medium VL endemicities (up to 5 
reported VL cases per 10,000 population per year) prior to the start of the interventions. 
However, in settings with higher pre-control endemicities, additional efforts may be required. 
Initial results from statistical forecasting also suggest that the 2020 elimination target is 
unlikely to be met everywhere, despite the success of the programme in reducing the 
incidence of cases.
How would improvements in the 
programme (such as decreasing time to 
diagnosis and improving efficacy of IRS) 
reduce the timelines to achieve the target.
Increasing the duration of the WHO attack phase from 5 (current guidelines) to 10 years in 
high pre-control endemicity settings (10/10,000/year) was simulated to bring the elimination 
target forward by at least 5 years10. Currently we are investigating how changes in detection 
delay and population coverage affect VL transmission and the timeline to achieving the 
target.
How can improvements of the programme 
to achieve a better case detection impact 
meeting the target of number of cases per 
block? 
As we noted above, the current target offers perverse incentives, as if case detection is 
poor, the target is more likely to be met, even though the region would then likely not meet 
the WHO validation of elimination criteria. This can potentially lead to underdiagnosis/
underreporting and large future outbreaks. Better data on the detection process would 
enable more detailed modelling. We are currently considering the impact of variation in 
detection success.
Priority questions
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